Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23530956 | 0.91 | KDR (0.31) | KLKB1KDR | |
| SCHEMBL23530869 | 0.90 | RAB9A (0.36) | KLKB1KDR | |
| SCHEMBL30370121 | 0.90 | KLKB1 (0.33) | KLKB1KDR | |
| SCHEMBL23530581 | 0.89 | KLKB1 (0.39) | KLKB1KDR | |
| SCHEMBL23531010 | 0.86 | LMNA (0.33) | KLKB1KDR | |
| SCHEMBL23530690 | 0.82 | KDR (0.31) | KDR | |
| SCHEMBL30370709 | 0.82 | GPR119 (0.31) | KDR | |
| SCHEMBL30370138 | 0.81 | RAB9A (0.34) | KLKB1KDR | |
| SCHEMBL30370439 | 0.81 | KLKB1 (0.36) | KLKB1KDR | |
| SCHEMBL23530928 | 0.81 | RBP4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | KLKB1 2395/4885KDR 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.